Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Amit Sachdev Sells 1,846 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 1,846 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $897,802.10. Following the completion of the sale, the executive vice president directly owned 55,570 shares in the company, valued at approximately $27,026,469.50. This trade represents a 3.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amit Sachdev also recently made the following trade(s):

• On Thursday, February 19th, Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79.

Vertex Pharmaceuticals Trading Down 0.6%

Shares of VRTX opened at $480.13 on Friday. The firm has a market cap of $121.97 billion, a PE ratio of 31.32 and a beta of 0.30. The company’s 50 day simple moving average is $465.74 and its 200-day simple moving average is $431.13. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $3.98 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: CEO Reshma Kewalramani profiled by TIME as a physician-scientist running one of biotech’s largest companies — positive PR that supports confidence in leadership and long-term strategy. Physician-Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Coverage asking whether VRTX is outperforming the Dow highlights recent relative strength and investor interest in Vertex’s growth profile — supports demand from momentum/quality investors. Is Vertex Stock Outperforming the Dow?
• Neutral Sentiment: Analyst/market commentary pieces (e.g., Nasdaq‑100 roundup) raise attention but are mixed in tone and not specific to new catalysts for Vertex. 2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
• Neutral Sentiment: Recent Q4 results (reported Feb. 12) showed revenue growth (~+9.5% y/y) and margin strength but a very slight EPS miss (reported $5.03 vs. $5.05 consensus). Fundamentals remain solid, but the tiny miss tempers upside catalysts in the near term.
• Negative Sentiment: Multiple insider sales disclosed in SEC filings — including a large sale by EVP Amit Sachdev (58,613 shares sold, ~$27.5M) and several sales by other executives on Feb. 25 — may be weighing on the stock as investors interpret reduced insider holdings as a negative signal (though sales can reflect diversification or tax planning). Representative SEC filing: SEC Form 4 – Amit Sachdev

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on VRTX shares. HC Wainwright set a $591.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 17th. Canaccord Genuity Group upped their target price on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research report on Tuesday, February 17th. Evercore increased their price target on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $590.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Finally, Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price objective for the company in a research report on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $542.00.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VRTX. Earned Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 3.3% during the fourth quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock worth $295,000 after buying an additional 21 shares during the period. Confluence Wealth Services Inc. lifted its stake in Vertex Pharmaceuticals by 4.0% in the 4th quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after acquiring an additional 21 shares in the last quarter. Williams Jones Wealth Management LLC. boosted its position in Vertex Pharmaceuticals by 1.9% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after acquiring an additional 21 shares during the last quarter. Childress Capital Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 3.1% during the 4th quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company’s stock worth $331,000 after acquiring an additional 22 shares in the last quarter. Finally, Kovack Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 1.9% in the second quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.